co-founders picture


David D. Ho, MD and
Yaoxing Huang, PhD

Drs. Ho and Huang have collaborated on several successful scientific projects over more than 25 years and have advanced multiple vaccine and antibody candidates from the bench to the bedside. RenBio is the fruition of their latest collaborative endeavor. 


David D. Ho, MD

Dr. Ho is the Founding Scientific Director of the Aaron Diamond AIDS Research Center and the Clyde and Helen Wu Professor of Medicine at Columbia University Vagelos College of Physicians and Surgeons. He has been at the forefront of AIDS research since the beginning of the epidemic and is a world-renowned infectious disease physician-scientist with over 500 scientific publications including those in Nature, Science, Cell, New England Journal of Medicine and Proceedings of the National Academy of Sciences. His seminal studies unveiling the dynamic nature of HIV replication in vivo have revolutionized our basic understanding of the disease. This knowledge led him to champion the groundbreaking approach of combination antiretroviral therapy that resulted in unprecedented control of HIV among patients. To date, more than 20 million patients worldwide have benefitted from combination antiretroviral therapy. As a major driving force in the fight to end the disease, Dr. Ho has received numerous honors and awards for his scientific accomplishments from his academic peers, national governments and the public at large. He is the recipient of a Presidential Citizens Medal, as well as 14 honorary doctorates. In addition to his election to the American Academy of Arts and Sciences and the


Yaoxing Huang, PhD

Dr. Huang is currently an Associate Professor of Medical Sciences at Columbia University Vagelos College of Physicians and Surgeons and has spent over 25 years conducting HIV research. He has authored over 45 publications on HIV pathogenesis, vaccine discovery and development, and antibody engineering and development. Dr. Huang has led or contributed to the discovery, characterization, and preclinical development of numerous therapeutic candidates including a DNA vaccine, attenuated viral vector vaccine, and antibody therapeutic for the prevention or treatment of HIV that were all selected for advancement to clinical evaluation.
meet the team data-lazy-srcset=
Meet the team data-lazy-srcset=

Neal N. Padte, Ph.D.

Chief Operating Officer & Chief Development Officer

Rachel A. Liberatore, Ph.D.


Ilija Atanasovski

Senior Project Manager I

Andrew D. Cameron, M.S.

Research Engineer II

Verónica Miguela Fernández, Ph.D.

Research Scientist I

Debnath Maji, Ph.D.

Research Engineer II

Robert Miller

Research Associate II & Lab Manager

Annelyn P. O’Rourke


Xin Kevin Yao, Ph.D.

Research Scientist II

Adam Zerihoun, M.S.

Research Associate II

Add Your Heading Text Here

Add Your Heading Text Here

Add Your Heading Text Here

Add Your Heading Text Here

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

minus data-lazy-srcset=